ストックスクリーナーアプリを入手
1.97
2.07%
0.04
アフターアワーズ：
2.00
0.03
+1.52%
前日終値:
$1.93
開ける：
$1.87
24時間の取引高:
10.18M
Relative Volume:
1.08
時価総額：
$579.80M
収益：
$188.87M
当期純損益:
$-400.38M
株価収益率:
-1.5512
EPS:
-1.27
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
+0.51%
1か月 パフォーマンス:
+14.53%
6か月 パフォーマンス:
+25.48%
1年 パフォーマンス:
-79.82%
1日の値動き範囲:
$1.85
$2.01
1週間の範囲:
$1.81
$2.13
52週間の値動き範囲:
$1.16
$10.65
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.97 | 579.80M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Fmr LLC Has $694,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences updates executive severance agreements By Investing.com - Investing.com Canada
Pacific Biosciences updates executive severance agreements - Investing.com India
Pacific Biosciences Updates Executive Severance Agreements - TipRanks
Pacific Biosciences of California, Inc. announced that it expects to receive $50 million in funding - Marketscreener.com
Long Read Sequencing Market Industry Dynamics - openPR
Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
BNP Paribas Financial Markets Reduces Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Pacific Biosciences names CEO as interim CFO By Investing.com - Investing.com Australia
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpHere's Why - MarketBeat
Pacific Biosciences names CEO as interim CFO - Investing.com
Soros Fund Management LLC Grows Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB (Pacific Biosciences of California) Net Issuance of Pr - GuruFocus.com
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight - Benzinga
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" from Analysts - MarketBeat
PacBio Reports Equity Incentive Awards to New Employees Under Na - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.4% HigherShould You Buy? - MarketBeat
Shrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034 - GlobeNewswire Inc.
SOFTBANK GROUP CORP. Acquires Significant Stake in Pacific Biosciences of California Inc - GuruFocus.com
PACB (Pacific Biosciences of California) 3-Year Revenue Gro - GuruFocus.com
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - Quantisnow
Senvest Management LLC Boosts Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Sumitomo Mitsui Trust Group Inc. Has $20.17 Million Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Research Analysts Offer Predictions for PACB FY2024 Earnings - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartzy
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% Following Analyst Upgrade - MarketBeat
Pacific Biosciences of California, Inc. Announces Resignation of Susan Kim as Chief Financial Officer, Effective December 6, 2024 - Marketscreener.com
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
UBS Downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates - MSN
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock - Investing.com
PacBio’s $459 Million Convertible Note Exchange Offering - Global Legal Chronicle
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00 - MarketBeat
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
大文字化:
|
ボリューム (24 時間):